A5011401640- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Acute Myocardial Infarction Research
- Diet and metabolism studies
- Metabolism, Diabetes, and Cancer
- Potassium and Related Disorders
- Semiconductor materials and devices
- Neuroendocrine Tumor Research Advances
- Renal function and acid-base balance
- Receptor Mechanisms and Signaling
- Trauma Management and Diagnosis
- Congenital Heart Disease Studies
- Pancreatic function and diabetes
- Cardiac pacing and defibrillation studies
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Medical University of Graz
2007-2025
University of Graz
2007
Sodium-glucose co-transporter 2 inhibition reduces the risk of hospitalization for heart failure and death in patients with symptomatic failure. However, trials investigating effects this drug class following acute myocardial infarction are lacking.
Abstract Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have been suggested to exert cardioprotective effects in patients with heart failure, possibly by improving the metabolism of ketone bodies myocardium. Methods This post hoc analysis EMMY trial investigated changes serum β-hydroxybutyrate (3-βOHB) levels after acute myocardial infarction (AMI) response 26-week Empagliflozin therapy compared usual post-MI treatment. In addition, association baseline and repeated...
Pharmacological post-MI treatment is routinely initiated at intensive/cardiac care units. However, solid evidence for an early start of these therapies only available dual platelet therapy and statins, whereas data on beta blockers RAAS inhibitors are heterogenous mainly limited to STEMI heart failure patients. Recently, the EMMY trial provided first beneficial effects SGLT2 (SGLT2i) when after PCI. In patients with type 2 diabetes mellitus, SGLT2i considered "sick days drugs" it, therefore,...
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial pleiotropic effects, contributing to improved cardiovascular and renal outcomes for patients with without diabetes. The impact of SGLT2is on arrhythmic burden remains largely unexplored through randomized trials.
Sodium glucose cotransporter 2 (SGLT2) have proven profound positive effects in heart failure with reduced ejection fraction (HFrEF). These are independent from the presence of diabetes. Metabolic effects, antiinflammatory, and antifibrotic properties discussed as underlying mechanisms. Despite a strong correlation ventricular arrhythmias HFrEF, impact ertugliflozin on arrhythmic burden has not been investigated, yet. Therefore, Ertugliflozin to Reduce Arrhythmic ICD ± CRT patientS (ERASe)...
Traumatic cardiac injuries are rare, but patients may present with symptoms like arrhythmias, heart failure, or cardiogenic shock. A 50-year-old Caucasian construction worker was admitted to our emergency department a new-onset third-degree atrioventricular (AV) block following traumatic blunt chest injury at work. The arrhythmia controlled by continuous application of isoprenaline. After stabilization, the electrocardiogram showed sinus rhythm left bundle branch block. Transthoracic...
Background: Cardiogenic shock (CS) exhibits high (~50%) in-hospital mortality. The recently published Extracorporeal life Support in Shock (ECLS-SHOCK) trial demonstrated the neutral effects of use veno-arterial extracorporeal membrane oxygenation (VA-ECMO) on all-cause death, as well all secondary outcomes subjects presenting with myocardial-infarction (MI)-related CS. Here, we compared ECLS-SHOCK eligibility criteria a real-world cohort CS patients. Methods and Results: were applied to...
Abstract The EMMY trial was a multicentre, investigator-initiated, placebo-controlled, double-blind trial, which enrolled 476 patients immediately following AMI and the first study demonstrating significant reduction in NT-proBNP-levels as well improvements cardiac structure function after acute myocardial infarction treated with empagliflozin vs. placebo. However, hardly any data are available investigating prognostic role of baseline electrocardiogram metrics SGLT2-inhibitor-treated...
Patients with acute myocardial infarction are at high risk for developing heart failure due to scar development. Although regenerative approaches evolving, consistent clinical benefits have not yet been reported. Treatment dutogliptin, a second-generation DPP-4 inhibitor, in co-administration filgrastim (G-CSF) has shown enhance endogenous repair mechanisms experimental models. The REC-DUT-002 trial was phase 2, multicenter, double-blind placebo-controlled which explored the safety,...
Human physiology has evolved to maintain blood pH values within a narrow range of 7.39 7.42. This is ensured by several buffering and accompanying adaptive mechanisms. Several organs are involved in this important regulation. The calcium carbonate/calcium phosphate system part the system. In present study we intended show influence acid-base on bone turnover (BT).